This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Biotech stocks have been among the best performers of the last five years, according to Investor Uprising Confidential's research, and many of these gains are driven by scientific innovation in the biopharmaceuticals and diagnostics markets. This innovation cycle is likely to continue for some time, making biotech an attractive place to invest.
"Many investors remain unaware of the strength in biotech and are mystified about how to invest in the market," says Investor Uprising Confidential's Editor and Publisher,
R. Scott Raynovich. "Consequently, they have missed out. We put together a report that covers all the trends and explains many different ways to get involved, including ETFs, mutual funds, and individual stocks."
The report includes summaries of 17 leading biotechnology companies, three mutual funds, and the leading biotech Exchange Traded Funds (ETFs). Among the companies included in the report are Amgen Inc. (Nasdaq: AMGN), Biogen Idec (Nasdaq: BIIB), Celgene Inc. (Nasdaq: CELG), Gilead Sciences Inc. (Nasdaq: GILD), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Cubist Pharmaceuticals Inc. (Nasdaq: CBST), Dendreon Corp. (Nasdaq: DNDN), Illumina Inc. (Nasdaq: ILMN), and Seattle Genetics Inc. (Nasdaq: SGEN).
Investor Uprising Confidential produces premium in-depth reports aimed at informing the sophisticated investor about long-term trends in important growth markets. The Best of Biotech report is available as a single copy at
$500, or as part of an Investor Uprising Confidential annual subscription. To look at the executive summary of the Biotech and the research service, go to
Sponsored by PR Newswire, Investor Uprising, as well as the recent launch of the "
My News" feature on PRNewswire.com and monthly virtual Retail Investor Conferences (retailinvestorconferences.com), represents PR Newswire's strategy to facilitate engagement between the individual investor community and public companies.
About Investor Uprising Investor Uprising is the individual investor's no-nonsense community for accessing business trends and investment strategies. Combining expert market commentary, fundamental analysis and on-the-ground reporting, Investor Uprising helps the reader find the best investment opportunities in global markets. Sponsored by PR Newswire and operated by UBM plc, Investor Uprising's community of contributors will reach millions of potential business readers around the world.
Media Contacts:R. Scott RaynovichEditor in Chief, Investor Uprising Confidential (406) 582-5886 direct(406) 599-7873 mobile
Scott.Raynovich@investoruprising.comNoreen Seebacher Community Editor, Investor Uprising(201) 360-6773
SOURCE Investor Uprising